European Commission Approves AMGEVITA ™ (Biosimilar Adalimumab) For The Treatment Of Certain Inflammatory Diseases

First Biosimilar Adalimumab Approved in the European Union THOUSAND OAKS, Calif., March 23, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has granted marketing authorization for AMGEVITA™ (biosimilar adalimumab1) in all available indications. AMGEVITA is authorized for the treatment of certain inflammatory diseases in adults, including moderate-to-severe rheumatoid arthritis; psoriatic arthritis; severe active ankylosing spondylitis (AS); severe axial spondyloarthritis without radiographic evidence of AS; moderate-to-severe chronic plaque psoriasis; moderate-to-severe hidradenitis suppurativa; non-infectious intermediate, posterior and panuve...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news